Bavarian Nordic (OTCMKTS:BVNRY) Announces Quarterly Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) announced its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.37%. The company had revenue of $165.70 million for the quarter.

Bavarian Nordic Price Performance

BVNRY stock remained flat at $9.69 during trading on Friday. The company’s stock had a trading volume of 2,165 shares, compared to its average volume of 5,213. The firm’s 50-day simple moving average is $9.85 and its 200 day simple moving average is $10.06. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of 12.75 and a beta of 1.21. Bavarian Nordic has a 1 year low of $8.11 and a 1 year high of $13.00.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.